CytomX Therapeutics (NASDAQ: CTMX) drew attention a few days ago after its six-year-old, up-to-$1.68 billion cancer collaboration with Astellas Pharma (Tokyo: 4503) was terminated by the Japanese pharma giant, but the setback hardly registered with investors of the South San Francisco, CA, biotech.
Instead, what drew investors to CytomX stock on March 16 was its announcement of positive dose expan...
The strongest version of this narrative highlights the high-stakes nature of biotech investing, where clinical trial results and analyst projections can drive dramatic stock movements. CytomX's varseta-M shows genuine promise, with a 32% response rate in a challenging cancer indication, and analysts like Jefferies' Roger Song provide a compelling case for its potential as a blockbuster drug. The subsequent stock volatility, however, underscores the fragility of investor confidence when faced wit...